At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Jun 1, 2026 at 08:30 ET
Disc Medicine launched an expanded access program (EAP) for bitopertin in erythropoietic protoporphyria (EPP)/X-linked protoporphyria (XLP) patients in the U.S., while noting that Phase 3 APOLLO topline data is expected in Q4 2026, with a CRL response and FDA decision expected by mid-2027. This is a procedural step that does not change the binary risk/reward of the upcoming Phase 3 readout and regulatory decision, and does not add new safety/efficacy data.
- EAP launched for bitopertin in eligible EPP/XLP patients aged 12+ in the U.S.
- Phase 3 APOLLO double-blind, placebo-controlled trial ongoing; topline data expected Q4 2026
- Disc Medicine expects to submit a CRL response with FDA decision by mid-2027
- Bitopertin is not approved in any jurisdiction; an earlier CRL prompted the updated timeline
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access